
01:01:50
Thank you for emphasizing the FDA's point of view of SOC treatment as a control arm.

01:04:17
some papers describe nanomedicine as that with particles that are less than 100nm (nanoparticles). So it seems that is too restrictive and technical definition of nanomedicine.

01:15:03
why cancer samples from different patients responded differently to drugs?

01:17:53
Targeting as you presented it is important for us in Chem / Bio Defense, too. As is the comment about comparing to standard of care.

01:22:06
@Kien - differences in intratumoral distribution and cancer cell heterogeneity are among key factors

01:32:20
Thanks Prof Park for the interesting seminar!

01:33:17
Great kickoff to this new series.